BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc.

The deal is valued at $270 million, and BioMarin Pharmaceutical Inc. has paid $4.00 per share in cash for all Inozyme shares. This acquisition brings a new medicine, INZ-701, into the company’s portfolio. INZ-701 is an enzyme replacement therapy in late-stage development. The drug targets ENPP1 Deficiency, which is a rare and severe genetic disorder that affects blood vessels, soft tissues, and bones.

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma

A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide.

The process began on May 16, 2025, when both companies announced a merger agreement. BioMarin Pharmaceutical Inc. then started a tender offer on June 2, 2025, and shareholders were offered $4.00 per share. The offer ended on June 30, 2025.

BioMarin Pharmaceutical Inc. is an international biotechnology company focused on developing and commercializing innovative therapies for rare genetic disorders.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.